Linkedin
RLS logo_header
Search
Close this search box.
Linkedin
Search
Close this search box.

Avacta and Tempus Enter Strategic Collaboration to Advance AI-Driven Drug Development in Oncology

Christina Coughlin, MD PhD, CEO of Avacta, said,“Our pipeline of pre|CISION® oncology programs will benefit greatly from an extensive understanding of the tumor microenvironment, FAP biology and both high- and low-FAP expression across solid tumor settings. The Tempus AI real-world database and industry-leading AI capabilities will enable us to better assess the specific patient population most likely to respond to our pre|CISION® therapies, enabling faster, smarter clinical development with the highest probability of success.”

Read the full story on "Avacta and Tempus Enter Strategic Collaboration to Advance AI-Driven Drug Development in Oncology"

Share:

More News

BeiGene Unveils Proposed Name Change to BeOne Medicines

“Cancer, a leading cause of death worldwide, exacts an immense toll on individuals, families, and communities. No person, family, scientist, clinician, hospital, policy maker, company or country can or should face this devastating disease alone. We all must work together to win, which is why we are committed to playing

Encouraging updated interim Ph 2 data from GRANITE trial in 1L MSS-CRC announced

“Our encouraging Phase 2 data for GRANITE in MSS-CRC continue to mature and demonstrate durable benefit over time. With two additional months of follow-up, relative progression-free survival has further improved in the analysis of all patients treated with GRANITE, and most notably, in those with a lower tumor burden at

Positive CHMP Opinion for Repotrectinib for the Treatment of Advanced ROS1-Positive NSCLC and Advanced NTRK-Positive Solid Tumors

“Patients in the EU with ROS1 -positive non-small cell lung cancer and NTRK -positive solid tumors face a great unmet need for new therapies that may improve their outcomes and address or delay the difficult issue of treatment resistance,” said Joseph Fiore, vice president, global program lead, repotrectinib, Bristol Myers

BioNTech to Acquire Biotheus to Boost Oncology Strategy

“The acquisition of Biotheus builds on our successful ongoing collaboration on BNT327/PM8002 and other investigational bispecific antibodies,” said Prof. Ugur Sahin, M.D., Ph.D., CEO and co-founder of BioNTech. “We believe that BNT327/PM8002 has the potential to set a new standard of care in multiple oncology indications, surpassing traditional checkpoint inhibitors.

Onco-This-Week

About Us

Sign up for OTW

Linkedin
Search
Close this search box.

Disclaimer: The OTW team takes care to share authentic information. In case of any discrepancies please write to newsletter@onco-this-week.com. Our website is an aggregator for open-source oncology news. The information on our website is provided without any representations or warranties. OTW is part of RLS Consultants, a global consulting and training firm focusing exclusively on the healthcare and life sciences industries. RLS is a leading provider of opportunity assessment services, utilizing its comprehensive expertise in strategic market research, forecasting, and modeling, as well as pricing and market access to facilitate commercial assessments. RLS does not have any influence on any news reported on OTW. The views and opinions expressed in this article are those of the authors and do not necessarily reflect the official policy or position of RLS. The content on our website is intended strictly for news and information purposes only and should not be treated as a substitute for medical advice, diagnosis, or treatment. News shared on OTW should not be utilized in real-world analytic products as they are based only on limited and dated open-source information.